Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence.

Albani D, Polito L, Forloni G.

J Alzheimers Dis. 2010;19(1):11-26. doi: 10.3233/JAD-2010-1215. Review.

PMID:
20061622
2.

Neuroprotective properties of resveratrol in different neurodegenerative disorders.

Albani D, Polito L, Signorini A, Forloni G.

Biofactors. 2010 Sep-Oct;36(5):370-6. doi: 10.1002/biof.118. Review.

PMID:
20848560
3.

Sirtuins: common targets in aging and in neurodegeneration.

de Oliveira RM, Pais TF, Outeiro TF.

Curr Drug Targets. 2010 Oct;11(10):1270-80. Review.

PMID:
20840069
4.

Neuronal protection by sirtuins in Alzheimer's disease.

Anekonda TS, Reddy PH.

J Neurochem. 2006 Jan;96(2):305-13. Epub 2005 Oct 7. Review.

5.

Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease.

Gan L.

Drug News Perspect. 2007 May;20(4):233-9. Review.

PMID:
17637936
6.
7.

Sirtuins in cognitive ageing and Alzheimer's disease.

Braidy N, Jayasena T, Poljak A, Sachdev PS.

Curr Opin Psychiatry. 2012 May;25(3):226-30. doi: 10.1097/YCO.0b013e32835112c1. Review.

PMID:
22327552
8.

Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications.

Aljada A, Dong L, Mousa SA.

Curr Opin Investig Drugs. 2010 Oct;11(10):1158-68. Review.

PMID:
20872319
9.

SIRT1 and neuronal diseases.

Tang BL, Chua CE.

Mol Aspects Med. 2008 Jun;29(3):187-200. Epub 2007 Feb 16. Review.

PMID:
17397914
10.

After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.

Huber K, Superti-Furga G.

Bioorg Med Chem. 2011 Jun 15;19(12):3616-24. doi: 10.1016/j.bmc.2011.01.018. Epub 2011 Jan 15. Review.

PMID:
21306906
11.

SIRTUIN 1: regulating the regulator.

Zschoernig B, Mahlknecht U.

Biochem Biophys Res Commun. 2008 Nov 14;376(2):251-5. doi: 10.1016/j.bbrc.2008.08.137. Epub 2008 Sep 5. Review.

PMID:
18774777
12.

SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase.

Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, Cohen RA, Zang M.

J Biol Chem. 2008 Jul 18;283(29):20015-26. doi: 10.1074/jbc.M802187200. Epub 2008 May 14.

13.

Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders.

Culmsee C, Landshamer S.

Curr Alzheimer Res. 2006 Sep;3(4):269-83. Review.

PMID:
17017859
14.

Sirtuins in aging and age-related disease.

Longo VD, Kennedy BK.

Cell. 2006 Jul 28;126(2):257-68. Review.

15.

Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker?

Lee J, Ryu H.

BMB Rep. 2010 Oct;43(10):649-55. doi: 10.5483/BMBRep.2010.43.10.649. Review.

16.

Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection.

Pallàs M, Casadesús G, Smith MA, Coto-Montes A, Pelegri C, Vilaplana J, Camins A.

Curr Neurovasc Res. 2009 Feb;6(1):70-81. Review.

PMID:
19355928
17.

Sirtuins: a family of proteins with implications for human performance and exercise physiology.

Lappalainen Z.

Res Sports Med. 2011 Jan;19(1):53-65. doi: 10.1080/15438627.2011.536068. Review.

PMID:
21253976
18.

Pharmaceutical strategies for activating sirtuins.

Sauve AA.

Curr Pharm Des. 2009;15(1):45-56. Review.

PMID:
19149602
19.

Role of protein conformational dynamics and DNA integrity in relevance to neuronal cell death in neurodegeneration.

Gupta VB, Hegde ML, Rao KS.

Curr Alzheimer Res. 2006 Sep;3(4):297-309. Review.

PMID:
17017861
20.

Sirtuins: the 'magnificent seven', function, metabolism and longevity.

Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J.

Ann Med. 2007;39(5):335-45. Review.

PMID:
17701476

Supplemental Content

Support Center